Does Septra Interact with Apixaban?
Yes, trimethoprim-sulfamethoxazole (Septra) does NOT have a clinically significant pharmacokinetic interaction with apixaban based on available evidence, but caution is still warranted due to potential additive bleeding risk.
Key Interaction Considerations
Pharmacokinetic Profile
Apixaban is metabolized primarily via CYP3A4 (with minor contributions from other CYP enzymes) and is a substrate of P-glycoprotein (P-gp) 1. The FDA label and guidelines specifically address interactions with combined strong CYP3A4 and P-gp inhibitors or inducers 2, 1.
Trimethoprim-sulfamethoxazole is not classified as a strong CYP3A4 inhibitor or P-gp inhibitor. The FDA drug label for apixaban does not list TMP-SMX among the drugs requiring dose adjustment 1. The 2022 Circulation guideline on DOAC drug interactions similarly does not identify TMP-SMX as a significant interacting agent 2.
What This Means Clinically
- No apixaban dose adjustment is required when co-administering with TMP-SMX based on pharmacokinetic considerations
- TMP-SMX does not fall into the categories requiring the 50% dose reduction (combined strong CYP3A4/P-gp inhibitors like ketoconazole, itraconazole, ritonavir) 1
- TMP-SMX is not a strong inducer requiring avoidance (like rifampin, carbamazepine, phenytoin) 1
Important Caveats
Bleeding Risk Considerations
While there is no direct pharmacokinetic interaction, be vigilant for additive bleeding risk through pharmacodynamic mechanisms:
- The FDA label warns that "coadministration of antiplatelet agents, fibrinolytics, heparin, aspirin, and chronic NSAID use increases the risk of bleeding" 1
- Although TMP-SMX is not specifically listed, any concurrent medication in an anticoagulated patient warrants bleeding risk assessment
Renal Function Monitoring
This combination requires particular attention to renal function:
- TMP-SMX can cause hyperkalemia and acute kidney injury, with risk increasing in patients with baseline renal impairment 3
- Apixaban exposure increases with declining renal function, and dose adjustments are based on creatinine clearance 1
- Monitor renal function closely when initiating TMP-SMX in patients on apixaban, especially if CrCl <50 mL/min
Limited Clinical Data
A 2014 review noted that "no published data were found for apixaban" regarding antibiotic interactions, though this was early in apixaban's clinical use 4. More recent cancer patient data showed no clear influence of drug interactions on apixaban clinical outcomes 5, though TMP-SMX was not specifically studied.
Practical Approach
You can safely prescribe TMP-SMX with apixaban without dose adjustment, but:
- Assess baseline renal function before starting TMP-SMX
- Monitor for bleeding signs during concurrent therapy (unusual bruising, bleeding gums, hematuria)
- Recheck renal function if TMP-SMX course exceeds 7-10 days or if patient has baseline CrCl <60 mL/min
- Educate patients to report bleeding symptoms immediately
- Consider shorter antibiotic courses when clinically appropriate to minimize exposure duration
This approach prioritizes patient safety while recognizing that the pharmacokinetic interaction risk is minimal 2, 1.